Flavors and fragrances, cosmetics, lubricants, surfactants, pesticides, fine chemicals, bioplastics, biofuels, detergents, adhesives, solvents, dispersants for dyes, textile finishing – the potential applications of bio-based alkanes and alkenes seem almost endless. At acib, we provide the tools to make this vision a reality.

Yeast surface display represents a powerful protein lab)
engineering technology, enabling a wide range of applications including the generation of novel antigen binding sites (also in non-antibody proteins), affinity maturation, construction of pH-dependent binding sites and protein stabilization, among many others.

We present an innovative approach to enhance safety and efficacy of mRNA vaccines by incorporate vasoconstrictors during preparation. By preventing unintended bloodstream entry and minimizing adverse effects our method addresses concerns surrounding vaccine safety, improving the effectiveness and general reception of established mRNA vaccines!

Cell-Free circulating DNA (cfDNA) is an incredible source of information on the health status of humans and animals. This largely untapped source of knowledge can be utilized to detect sepsis earlier than ever before and independent of the causing pathogen.

Ever wondered how to produce essential pharmaceuticals more affordably and sustainably? acib is going to revolutionize the production of plant-derived bioactive molecules by developing a plant cell-based, bioreactor-compatible technology to defeat the limitations of traditional manufacturing approaches. Check it out …

Understanding the intricacies of metabolite fingerprints, their variations and absolute concentrations is paramount for a diverse array of studies. This includes biomarker studies, mechanistic inquiries, metabolic engineering endeavors, or quality assessments of complex mixtures.

acib has spearheaded for over a decade an international collaborative effort to unlock the potential of CHO-cells, addressing the main challenges of cell-line optimization. Benefit from reduced time-to-market and lower production cost and let acib streamline your process!

Antibiotic resistance is growing worldwide, while consumers urgently demand antibiotic-free products… What if there would be a new tool to fight the danger of pathogens that is effective and environmentally friendly

Harnessing the huge potential of biotechnology for new, sustainable and cost-effective production of high-value cosmetic ingredients has become a reality.

The research field of polymer & environmental biotechnology focusses on the development of biotechnical and enzymatic strategies related to polymer / material processing and environmental aspects. The expertise ranges from function-based enzyme development, in silico screenings and enzyme activation to estimate the biodegradation and fermentation pilots.​

Did you know that food waste valorisation is currently at the centre of debates on the development of various “circular bioeconomy“ models? Fruit waste, in particular, represents an incredible sustainable and renewable reserve for the extraction and/or production of various products, which include well the production of biopolymers for food packaging.

3D-bioprinting is revolutionizing research and medicine by enabling the precise creation of intricate 3D structures using both living cells and biomaterials. Let acib help you capitalize on this technology to advance novel scaffolds, tissue engineering, drug testing and personalized medicine!

If life science would be a country, it would rank third in plastic waste production, and 5th in CO2 emission. We need to become more sustainable in terms of energy and plastic use. Sterilization before, and inactivation after use requires vast amounts of energy and water, while single use plastics are from petrochemical plastic and are incinerated after use.

Ginseng is among the most famous health-promoting plants in the world. But did you know that ginseng has a very high cost of production? acib is going to change that by developing an industrial yeast for ginsenoside production and is looking for interested companies!​

Did you know that cholesterol is absolutely vital for our cells and a very popular ingredient in a wide range of cosmetics? Did you also know that cholesterol is animal derived, and naturally produced vegan cholesterol is painfully missing on the market? Let’s change that with acib’s cholesterol-producing yeast!

Europe’s Green Deal largely depends on lithium imports, but there are environmental concerns against mining in Europe. What if there would be a green, environmentally-friendly ‘bio-mining’ alternative for Europe?

Compact advanced training for biopharma with laboratory training for employees of pharmaceutical companies without relevant biotechnology training

As secondary metabolites are produced with the purpose to confer a selective advantage of the host organism they are an excellent source of novel bioactive compounds with great therapeutic potential for e.g. anti-biotics, anti-viral drugs and biological fungicides.

Growth factors are essential components in cell culture medium for pharmacological products as well as for cultivated meat production and also pharmaceuticals on their own. Still, their application is hampered by their folding instability.

You want to save money on expensive fermentation processes and speed them up? Young and viable cells provide a better fermentation performance. acib’s technology rejuvenates your yeast culture to increase process productivity withouth affecting other parameters.

Immune evasion is a hallmark of cancer, contributing signifcantly to the progression of malignancies and associated mortalities. An interdisciplinary approach lead by acib can assess personalized treatment options for patients, as well as lay the foundation to designing novel treatments.

You want healthy drinks with all the valuable ingredients and a good taste, but without or at least with less sugar? The good news is: You are not alone! The bad news is: It’s difficult to achieve with current technologies … Let’s develop some better ones!

acib has developed a new diagnostic tool for early sepsis detection through novel biomarkers based on circulating-free nucleic acids. The test allows for detection of sepsis 2-3 days before first symptoms occur and shows >80% accuracy.